Physiological and Psychological Effects (DASS21-CORT)

February 2, 2026 updated by: Mehmet Kaplan, Bingol University

The Effects of Short-term Motivational Factors and Calisthenic Exercise on Blood Cortisol Levels, and Symptoms of Depression, Anxiety, and Stress in Young Adults

Stress-related mental health problems such as depression, anxiety, and stress are common among young adults and are often linked to both psychological and physiological changes in the body. One of the key biological markers of stress is cortisol, a hormone released in response to stress. Elevated cortisol levels over time may negatively affect both mental and physical health. Although regular physical activity and relaxation-based approaches are known to reduce stress, it is not yet clear whether short-term, easily applicable interventions can produce measurable benefits, especially when motivational strategies and exercise are combined.

The purpose of this study is to evaluate the effects of short-term motivational factors and a single session of calisthenic exercise on blood cortisol levels and symptoms of depression, anxiety, and stress in young adults. Motivational factors in this study include group-based activities, diaphragmatic breathing, and stretching exercises, which are designed to increase engagement and relaxation without requiring intense physical effort. Calisthenic exercise refers to bodyweight-based movements that can be performed without special equipment and are accessible to most individuals.

This randomized controlled trial compares three groups: one group receiving motivational factors followed by a single session of calisthenic exercise, a second group receiving motivational factors only, and a control group receiving no intervention. By measuring blood cortisol levels and self-reported symptoms of depression, anxiety, and stress before and after the intervention, the study aims to determine whether these short-term interventions can lead to meaningful psychological and physiological improvements.

The main question this study seeks to answer is whether a brief, single-session intervention combining motivational strategies and calisthenic exercise is more effective than motivational strategies alone or no intervention in reducing stress hormone levels and psychological distress in young adults. Additionally, the study explores whether lifestyle and sociodemographic factors, such as exercise habits, sleep patterns, and perceived economic status, are associated with cortisol levels.

The findings of this study may help identify simple, low-cost, and time-efficient approaches that can be used to support stress management and mental well-being in young adult populations, particularly in university settings.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
84

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Bingöl
      • Merkez, Bingöl, Turkey (Türkiye), 12000
        • Bingol University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Individuals who voluntarily agreed to participate.
  • Individuals aged between 18 and 25 years.
  • Individuals who had not engaged in regular exercise (at least three days per week) within the past six months.
  • Individuals with no diagnosed psychiatric disorder.
  • Individuals with no chronic health condition.
  • Individuals who did not use any substances.

Exclusion Criteria:

  • Individuals who did not agree to participate in the study.
  • Individuals who completed the baseline (pre-intervention) assessment but did not complete the post-intervention assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control
No intervention was applied to this group.
Experimental: MF group
Only motivational factors were applied to this group. As motivational factors, participants performed diaphragmatic breathing exercises and stretching exercises in groups.
Other: Motivational factors
A 15-minute motivational factors intervention was applied.
Experimental: MF+CE group
Motivational factors and calisthenic exercises were applied to this group. First, motivational factors were implemented in groups, followed by calisthenic exercises.
Other: Motivational factors
A 15-minute motivational factors intervention was applied.
Other: Calisthenic exercise and Motivational factors
Following a 15-minute motivational factors intervention, a 30-minute calisthenic exercise program was implemented.
Other Names:
  • CE and MF

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
DASS-21
Time Frame: Immediately before and immediately after the single 45-minute exercise session
It is scored between 0 and 63. Higher scores indicate higher levels of depression, anxiety, and stress.
Immediately before and immediately after the single 45-minute exercise session
Cortisol
Time Frame: Immediately before the exercise session and 20 minutes after completion of the single exercise session

Blood cortisol concentration will be measured in µg/dL using a standardized laboratory assay.

A value of 17 µg/dL is considered a commonly used reference threshold, with values above this level generally indicating higher physiological stress and values below this level indicating lower physiological stress.
Immediately before the exercise session and 20 minutes after completion of the single exercise session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bingol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 2, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 19, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 20, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 2, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 10, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BAP-SHMYO.2025.001 (Other Grant/Funding Number: Bingol University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the dataset contains sensitive personal and biological information, and data sharing was not included in the informed consent obtained from participants.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings